Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 16,900 shares, a decline of 28.1% from the September 15th total of 23,500 shares. Currently, 1.4% of the company’s shares are sold short. Based on an average daily trading volume, of 770,200 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 770,200 shares, the short-interest ratio is currently 0.0 days. Currently, 1.4% of the company’s shares are sold short.

Xenetic Biosciences Stock Down 4.1%

Shares of NASDAQ XBIO opened at $3.71 on Thursday. Xenetic Biosciences has a 52 week low of $2.20 and a 52 week high of $13.93. The stock has a market capitalization of $5.71 million, a price-to-earnings ratio of -1.86 and a beta of 2.42. The firm has a 50-day simple moving average of $3.65 and a 200-day simple moving average of $3.28.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.19. Xenetic Biosciences had a negative net margin of 126.08% and a negative return on equity of 54.56%. The business had revenue of $0.59 million during the quarter, compared to analysts’ expectations of $0.48 million. As a group, equities research analysts expect that Xenetic Biosciences will post -1.01 EPS for the current year.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently raised its stake in Xenetic Biosciences stock. Sachetta LLC raised its position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 15,259 shares of the company’s stock after buying an additional 4,593 shares during the quarter. Sachetta LLC owned about 0.99% of Xenetic Biosciences worth $60,000 as of its most recent filing with the SEC. 15.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce”.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.